Cargando…
Utilization of genetic information for medicines development and equitable benefit sharing
Advances in genomic research have significantly enhanced modern drug development. However, equitable benefit sharing of the results of scientific advancement has not always been achieved. This paper shows how molecular biology has modified medicines development while also leaving open significant ch...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300349/ https://www.ncbi.nlm.nih.gov/pubmed/37388927 http://dx.doi.org/10.3389/fgene.2023.1085864 |
_version_ | 1785064568574181376 |
---|---|
author | Matsuyama, Kotone Kurihara, Chieko Crawley, Francis P. Kerpel-Fronius, Sandor |
author_facet | Matsuyama, Kotone Kurihara, Chieko Crawley, Francis P. Kerpel-Fronius, Sandor |
author_sort | Matsuyama, Kotone |
collection | PubMed |
description | Advances in genomic research have significantly enhanced modern drug development. However, equitable benefit sharing of the results of scientific advancement has not always been achieved. This paper shows how molecular biology has modified medicines development while also leaving open significant challenges for benefit sharing. Presented here is a conceptual modeling describing the processes in genetic-related medicines development and how these are related to specific ethical considerations. The focus is on three important areas: 1) population genetics and the need for discrimination prevention; 2) pharmacogenomics and the need for inclusive governance; and 3) global health to be achieved in open science frameworks. Benefit sharing is taken as the ethical value that underlies all these aspects. The implementation of benefit sharing requires a value shift in which the outcomes of health science are not viewed simply as trade commodities but also as a “global public good”. This approach should lead to genetic science to contribute to promoting the fundamental human right to health to all members of the global community. |
format | Online Article Text |
id | pubmed-10300349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103003492023-06-29 Utilization of genetic information for medicines development and equitable benefit sharing Matsuyama, Kotone Kurihara, Chieko Crawley, Francis P. Kerpel-Fronius, Sandor Front Genet Genetics Advances in genomic research have significantly enhanced modern drug development. However, equitable benefit sharing of the results of scientific advancement has not always been achieved. This paper shows how molecular biology has modified medicines development while also leaving open significant challenges for benefit sharing. Presented here is a conceptual modeling describing the processes in genetic-related medicines development and how these are related to specific ethical considerations. The focus is on three important areas: 1) population genetics and the need for discrimination prevention; 2) pharmacogenomics and the need for inclusive governance; and 3) global health to be achieved in open science frameworks. Benefit sharing is taken as the ethical value that underlies all these aspects. The implementation of benefit sharing requires a value shift in which the outcomes of health science are not viewed simply as trade commodities but also as a “global public good”. This approach should lead to genetic science to contribute to promoting the fundamental human right to health to all members of the global community. Frontiers Media S.A. 2023-06-14 /pmc/articles/PMC10300349/ /pubmed/37388927 http://dx.doi.org/10.3389/fgene.2023.1085864 Text en Copyright © 2023 Matsuyama, Kurihara, Crawley and Kerpel-Fronius. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Matsuyama, Kotone Kurihara, Chieko Crawley, Francis P. Kerpel-Fronius, Sandor Utilization of genetic information for medicines development and equitable benefit sharing |
title | Utilization of genetic information for medicines development and equitable benefit sharing |
title_full | Utilization of genetic information for medicines development and equitable benefit sharing |
title_fullStr | Utilization of genetic information for medicines development and equitable benefit sharing |
title_full_unstemmed | Utilization of genetic information for medicines development and equitable benefit sharing |
title_short | Utilization of genetic information for medicines development and equitable benefit sharing |
title_sort | utilization of genetic information for medicines development and equitable benefit sharing |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300349/ https://www.ncbi.nlm.nih.gov/pubmed/37388927 http://dx.doi.org/10.3389/fgene.2023.1085864 |
work_keys_str_mv | AT matsuyamakotone utilizationofgeneticinformationformedicinesdevelopmentandequitablebenefitsharing AT kuriharachieko utilizationofgeneticinformationformedicinesdevelopmentandequitablebenefitsharing AT crawleyfrancisp utilizationofgeneticinformationformedicinesdevelopmentandequitablebenefitsharing AT kerpelfroniussandor utilizationofgeneticinformationformedicinesdevelopmentandequitablebenefitsharing |